Edesa Biotech (NASDAQ:EDSA) soars 66% premarket after filing an IND application with the FDA to initiate a Phase 2/3 clinical study of EB05, for the treatment of hospitalized COVID-19 patients.
The company plans to enroll up to 450 patients in the first phase. Patients will be infused with a single dose of EB05 or placebo.
EDSA also received expedited approval in Canada to begin the Phase 2/3 study and is seeking government grants to initiate patient enrollment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.